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Health care institutions across the world are facing chal-
lenges in the delivery and provisioning of services with
financial solvency. Patient care now competes with
the financial solvency of the health care institutions
(Silverman, 2000), and the issue of ethics has become more
relevant than at any other point in time. Health care
services have a special moral quality. The purposes of health
care services include saving lives, preventing or relieving
suffering, preventing and curing disease and disability, and
ameliorating the consequences of disease when it cannot be
prevented or cured. Few people can be morally comfortable26993046.
in (V. Srinivasan).
ian Institute of Management
anagement Bangalore. Productio
2.11.004with the idea that some people should be denied access to
health care that might relieve their suffering or save their
lives because they cannot pay for it (Enthoven, 1993). In the
Indian context, where health indicators of the country are
poor, the discourse on ethics assumes greater complexity
and requires a more nuanced understanding and apprecia-
tion of the contextual elements. This note attempts to
provide a brief overview of the field of ethics in health care,
the status of the health care sector in India, the key insti-
tutional actors and finally, the key ethical issues arising out
of the interactions across the various actors.
Ethics and health care
The field of medical ethics has long existed, arising from
the Hippocrates oath, and tenets of the early religious
healing traditions of the West. Several Asian traditions have
also had ethical tenets governing the physicianepatient
relationship (Tsai, 1999; Desai, 1988). In the field of
contemporary medical ethics, the doctors in the USA were
the first to develop a modern code of ethics. At the first
meeting of the American Medical Association (AMA) in 1846,n and hosting by Elsevier Ltd. All rights reserved.
Table 1 Average cost (in rupees) of a typical illness
episode in public and private sector.
Public
facilities
Private
facilities
Cost of an out-patient episode 242 310
Cost of an in-patient episode 859 9352
Source: Selvaraj & Karan, 2009
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for the organisation. Modern medical codes of ethics are
based on the works of Thomas Percival, a British Physician
credited with giving much thought to the future of the
profession. The International Code of the World Medical
Association, an organisation representing physicians foun-
ded in 1947, ensures that physicians strive for the highest
possible standards of ethical behaviour and care at all times
(Backof & Martin, 1991).
In the 1970s, traditional medical ethics changed into an
interdisciplinary field involving theologians, lawyers,
philosophers, social scientists, and historians, as well as
physicians and other health professionals (Veatch, 2006).
The reason for this was the increasing impact of science and
technology, the growth of specialisation in the field of
medicine, public expectations from new medicines and
surgical techniques, changes in the financing and delivery of
health care, and the transformation of medical schools into
largemedical centres in theWest. The field ofmedical ethics
which focused on the moral responsibility of a physician to
a patient was not adequate to address the ethical aspects
emerging out of the changed context. With more stake-
holders, such asmedical devices companies, pharmaceutical
companies, diagnostic clinics, insurance companies, clinical
trial organisations, and other service providers entering the
field, there was a need to expand the scope of the definition
of ethics within the field of medicine. In recent years, the
terms “bio-medical ethics”, “bio-pharmaceutical ethics”,
and “health care ethics” are gaining importance. The term
bio-medical ethics includes the issues related to reproduc-
tive biology, such as stem cell research and human cloning
and the ethical dimensions arising out of these changes. The
term bio-pharmaceutical ethics refers to the ethics associ-
ated with the discovery and development of the products.
The term health care ethics is increasingly being used as an
umbrella term to encompass ethical aspects previously
included in medical-, bio medical-, bio-pharmaceutical- and
also organisational- and business ethics of different stake-
holders involved in the provisioning and delivery of health
care services. It is this broad definition of health care ethics
that is being used in this note and the round table discussion
that follows the note.
Indian health care sector
The health indicators of India have consistently lagged
behind the economic development that has been witnessed
over the last decade and the need for increased investment
in health care has been acknowledged. The public expen-
diture on health in India remained at about 1.1% of GDP in
2010 (Ministry of Health and Family Welfare, GOI). Public
health care delivery is done through a network of over
146,036 health sub-centres, 23,458 Primary Health Centres
(PHCs) and 4276 Community Health Centres (CHCs). There is
a 150-bed civil hospital at the district level to provide
tertiary care. Only 23.5% of urban population and 30.6% of
the rural people choose government facilities, thus reflect-
ing the widespread lack of confidence in the public health
care system (Central Bureau of Health Intelligence, 2010).
Studies have acknowledged that India ranks among the
top 20 countries in the world in its private health care
funding and that 82% of the total medical expense in India ispaid for through personal funds (Sengupta & Nandy, 2005).
According to the Central Bureau of Health Intelligence,
majority of Indians trust and visit private health care
despite the fact that cost of treatment in private treatment
is significantly higher than public facilities (Table 1).
Private sector health care is highly fragmented with over
90% of private health care being serviced by the unorgan-
ised sector. Eighty percent of the private hospitals are small
clinics and nursing homes (less than 30 beds). Six to seven
percent are 100e200 bed size hospitals and only 2e3% of
hospitals are 200- plus bed (Table 2). Most of the large
hospitals are located in the urban areas.
The sector however has attracted considerable private
investments and it appears that the participation of the
private sector in this field is likely to continue in the near
future. The conflict between the financial solvency of the
private sector players to the need for affordable quality
health care services in ways that enhance the health and
well-being of citizens is an immediate and visible area of
ethical conflict in the sector.
Disease burden and adequacy of facilities
In the course of development, countries undergo an
“epidemiologic transition”. Initially the developing nations
have high morbidity and mortality due to communicable
diseases and maternal and child mortality. As economic
development occurs, these morbidities decline significantly
and there is an upsurge of diseases of the affluent class,
that is, non-communicable diseases, injuries and geriatric
problems. India, however, faces a dual burden of high
incidence of infectious diseases (Tables 3 and 4) and a rising
epidemic of non-communicable diseases. The trend of dual
burden is consistent across urban and rural areas with
a slightly higher proportion of non-communicable diseases
in urban areas (Table 5). With the changing trends in the
communicable diseases, changing demographics, increasing
urbanisation, and increased lifespan, the burden of disease
is likely to increase further, putting a burden on an already
insufficient health care system.
Given the cost of treatment, disease burden, and the poor
public health care facilities, the moral and ethical discussion
on the “right to live” assumes a greater significance in India.
In the next section, we introduce the typical experiences of
an imaginary patient in the health care system in India.
An imaginary patient
This section outlines the trajectory for an imaginary patient
(Patient X) traversing through the value chain in Indian health
care. Patient X might be a poor farmer, an entrepreneur, or
Table 2 Classification of hospitals in India.
Types of hospitals in India
Government Private
Nursing homes Mid tier Top tier
Health care centres,
district hospitals
and general hospitals
Primarily nursing
homes and recovery
rooms with adequate
infrastructure
Corporate hospitals
with in house staff
and consulting physicians
Major corporate hospital
chains and specialty hospitals
Variable: based on types <30 beds 30e100 beds >100 beds
Source: Ministry of Health and Family Welfare, 2010, http://mohfw.nic.in/index.php
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who advises diagnostic tests, and cautionary medicines and
could also refer X to a specialist. Patient X has bills to pay and
the following options of payment: if Patient X has been
treated at a public hospital she may have the option of not
paying any of the bills; Patient X could approach her insurance
provider if she is employed in a big company and has
employer-provided insurance; Patient X could approach her
insurance provider from the state if she comes from below-
the-poverty-line and has state provided insurance. Despite
the options, it is an arduous journey, and one hopes, without
serious implications.
The above anecdote is educative of how as a patient or
a consumer, one is dependant on so many stakeholders
across the value chain in the Indian health care industry.
There are the doctors e the generalists and the specialists,
the medicine-makers, local firms and multinational corpo-
rations (MNCs), and the diagnostic device producers e
domestic and multinational e supplying their equipment to
the hospitals who can afford them. Finally there is the
concerned insurance provider to turn to for settling the
bills, provided one is among the privileged few in society to
have insurance support.
A brief overview of the key stakeholders in the value
chain is provided in Fig. 1. It must be noted that several
private and public actors are present in different parts of
the value chain. Therefore, the inter-relationships across
the actors are complex and raise several issues pertaining
to conflicts of interest.Table 3 Pattern of communicable diseases.
Trends of communicable diseases in India
Diseases showing
increasing trends
Diseases showing
decreasing trends
Dengue, chikungunya Poliomyelitis
HIV-TB co-infection Tuberculosis
Cholera O139 Neonatal tetanus
Japanese encephalitis Measles
Leptospirosis HIV/AIDS
Novel H1N1 infections
Eradicated: smallpox, guinea worm
Eliminated: yaws, leprosy
Source: Ministry of Health and Family Welfare, 2010, (http://
mohfw.nic.in/index.php)Health care is a key aspect of any developing nation and
the need for quality, accessible and affordable health care
is a necessity. A particularly central role in health care
delivery in modern societies is that of the physician. Francis
Moore the respected American physician noted, that “the
surgical investigator must be a bridge tender, channelling
knowledge from biological science to the patient’s bedside
and back again”, adding also that the surgical investigator
was open to the charge of not being a very good scientist
from one end of the bridge and of not spending enough time
in the operating room, from the other (Murray & Moore,
2002). In contexts like India, the role of the physician is
more nuanced and tricky, especially since physicians have
been historically revered in the society and their decision-
making powers are further enhanced. But such a role also
brings along with it responsibility. It is arguable if the two
key nodal organisations of physicians in the country, the
Medical Council of India (MCI) and the Indian Medical
Association (IMA) have been able to live up to that
responsibility in recent times.
Institutional structures and ethics
The IMA, organised in 1928, was the result of efforts in Cal-
cutta to form an association of doctors in pre-independence
India. It currently has over 178,000members with about 1700
local branches. With antecedents that can be traced to the
Bengal Medical Association, IMA has historically seen
respected doctors as its president. A key name in this regard is
Dr. B C Roy in 1929e1930 who later on became the Chief
Minister of West Bengal. (However, in recent times, the
reputation of the presiding doctors has been in question.) It is
also important to note that the IMA has played a global roleTable 4 Burden of communicable diseases.
Communicable
diseases
Magnitude of the burden
TB 283 cases per lakh population
in 2007
HIV 2.27 million HIV-positive
persons in 2008
Malaria 2 million deaths per year
Leprosy 130,000 affected people
Source: Ministry of Health and Family Welfare, 2010, (http://
mohfw.nic.in/index.php)
Table 5 The causes of death.
Causes of death Overall Rural
areas
Communicable
diseases, maternal,
peri-natal and
nutritional
38% 41%
Non-communicable
diseases
42% 40%
Injuries 10% 10%
Ill-defined causes 10% 9%
Source: Ministry of Health and Family Welfare, 2010, (http://
mohfw.nic.in/index.php)
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Medical Association and IMAmembers were also influential in
the setting up of the World Medical Association in 1962. At
around the time of IMA’s formation, the Medical Council of
India (MCI) was established in 1934 under the Indian Medical
Council Act, 1933. The Council was later reconstituted under
the IndianMedical Council Act, 1956 that replaced the earlier
Act. The main functions of the MCI are the following: estab-
lishment and maintenance of uniform standards for under-
graduate medical education; regulation of postgraduate
medical education in medical colleges accredited by it (The
National Board of Examinations is another statutory body for
postgraduate medical education in India); recognition of
medical qualifications granted by medical institutions in
India; recognition of foreign medical qualifications in India;
accreditation of medical colleges; registration of doctors
with recognised medical qualifications; and maintaining
a directory of all registered doctors (called the IndianMedical
Register). Finally, registration of doctors and their qualifica-
tions is usually done by state medical councils.Figure 1 Health care value chain in India. SouOn 25th June 2012, the nation witnessed an unprece-
dented one-day strike by the IMA1which contested the
proposed promulgation of the Clinical Establishments Act and
the formation of the National Council for Human Resources in
Health (NCHRH) by the Government of India. Physicians
across the country affiliated to IMA could foresee through
these developments, a diminishing role of IMA in Indian
society. This event followed Bollywood actor Aamir Khan’s
show on national television channels highlighting the
controversial roles of doctors around the country.2 These
events were not in isolation e coming after the arrest of the
MCI president Dr. Ketan Desai by the Central Bureau of
Investigation for allegedly accepting a bribe to permit
Patiala-based Gyan Sagar Medical College to recruit a fresh
batch of students without having adequate infrastructure.3
Subsequent to this, MCI was superseded by the President of
India and its functions entrusted to a Board of Governors. The
present Board of Governors was notified on 13 May 2011.
It is clear that while doctors have a bridging role to play
as alluded to by Francis Moore e their position is particu-
larly under the radar today in India. A recent article
effectively points to this, highlighting the role of “doctors
in entrepreneurial gowns”, and pointing to how various
private-sector physicians are also holding a conflicting
position with the IMA and are breeding industries such as in
the “treatment of obesity” (Nagral, 2012).
At various points in this round table discussion, we come
back to the key role of physicians and doctors in our lives.
While we certainly try to outline the role of firm-level
instruments and address issues for pharmaceutical firms,
domestic and multinational, and further discuss issues
about harmonisation of various regulatory bodies, physi-
cians e being central to the act of health care delivery e
have a key role to play in the context of ethical behaviour
in health care markets. They form a key component of our
discussion.rce: (Chandwani, Devare & Srinivasan, 2011)
Box 1. Key issues covered in the round
table.
The bio-pharmaceutical industry
a. Pricing of drugs (brand vs. generic)
b. Investments of MNCs in tropical disease drug
discovery to life style
c. Advertising e information disclosure in ads;
doctor-pharmaceutical firm nexus to promote
certain drugs over others through samples, spon-
sorship and other practices, with little attention
to quality
d. Availability of banned drugs and counterfeits.
e. Disregard of regulations in sponsoring clinical trials
f. Private health care providers and the issue of
“inappropriate care”.
Physician
a. Irrational prescription of drugs
b. Prescription by brand names instead of equivalent
generics
c. Commission received for referrals to diagnostic
centres
d. Prescription of non-essential drugs
e. Monitoring of the Medical Council of India and its
code-of-conduct.
Pharmacy/chemist
a. Use of the MRP as the price
b. Collusion by pharmacists on price
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underlining the issue of ethics and efficiency as they relate
to health care markets. This is a particularly salient guiding
framework since it is important to note that what might be
ethical might not necessarily be efficient and with the
particular case of health care markets this problem might
be aggravated. Andrew Shleifer (2004) discusses this trade-
off, pointing out that: “When unethical behavior cuts costs,
competition drives down prices and entrepreneurs’
incomes, and thereby reduces their willingness to pay for
ethical conduct. However competition might be good for
ethical behavior in the long run, because it promotes
growth and raises incomes. Higher incomes raise the will-
ingness to pay for ethical behavior, but may also change
what people believe to be ethical for the better.” With
regard to child labour, Shleifer points out that in many parts
of the developing world, without good access to capital
markets and educational opportunities, the alternative to
child labour could well be malnutrition and disease.
Thus the overlying issue of ethics and efficiency is
important and among other elements can be guided by two
key firm-level instruments that Dr. Manning outlines. Both
of these instruments could enhance or destroy social
welfare depending on how they are used and relate to
pricing and marketing methods used by pharmaceutical
firms. In the context of India this is particularly pertinent
with a large section of the population having inadequate
access to medicines, more so patented ones sold by
multinationals at prices far beyond their reach. Dr. Manning
raises the possibility of an important policy lever of
differential pricing and wonders whether it might have the
potential to address this problem. Theoretically speaking,
marketing and promotional activities might have an infor-
mational contribution about products such as medicines.
Dr. Manning alludes to them, but in the context of India this
is again salient since it might not be used by firms as a social
good. The Indian Medical Association is currently consid-
ering this particular area in careful detail and contem-
plating regulations to be put in place for implementing
checks on marketing and promotion activities of firms; it is
but pertinent that Dr. Manning’s thoughts would ring a bell
in that policy discussion.
The next speaker at the round table, Mr. Rijit Sengupta
extends Dr. Manning’s thoughts. An overarching theme of
Mr. Sengupta’s views is the role of non-market mechanisms
in ensuring ethical behaviour within the context of Indian
health care markets. He terms these as the twin roles of co-
regulation and self-regulation, his thoughts falling broadly
under three key aspects that economists have earlier
pointed to in their efforts to raise the willingness to pay for
ethical conduct: those of long run market pressures, moral
suasion, and governmental regulation.
Carrying forward Mr. Sengupta’s thoughts, Mr. Deepak
Sapra from Dr. Reddy’s Laboratories points out to issues
around “wellness” for an emerging economy like India.
Several of Mr. Sapra’s thoughts ring a bell with issues
highlighted earlier by Dr. Manning or Mr. Sengupta; in
particular with the role of pricing, drug discovery, and
research in neglected diseases. As an alumnus of IIM Ban-
galore it is also heartening to notice Mr. Sapra pointing to
the game-changing role that digitisation and information
technology can play in reducing uncertainty of the naturethat Arrow (1963) has highlighted as historically prevailing
in health care markets around the world, more so in India.
Mr. Sapra’s thoughts are given logical completion by Dr.
Ravikumar Banda, Founder and Managing Director of Xcyton
Diagnostics. Dr. Banda an erstwhile physician and now an
entrepreneur starts off by highlighting the “physician-
centricity” of health care markets, more so in contexts like
India. Dr. Banda’s thoughts particularly are contextual in
relation to the role of the MCI and the IMA, the two key
nodal bodies of physicians in the country. Dr. Banda touches
upon various aspects where society and these institutions
need to buckle up and raise their voices when it comes to
how physician behaviour affects the ordinary Indian citi-
zen’s life. Dr. Banda also brings out in his discussion the
pivotal role of the Central Drug Controller General of India
in installing formal regulatory systems to promote ethical
behaviour in Indian health care markets.
We highlight in Box 1, the key issues that get covered in
the round table. The area is vast and there are several
54 C. Chatterjee, V. Srinivasanissues around ethical behaviour in the context of health
care markets in India that merit attention. With the pres-
ence of international and domestic participants, experts
from consulting and not-for-profit institutions, the phar-
maceutical industry and a physician e we have attempted
in the discussion, to make a fair representation of all issues
under the overarching theme.
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The theme of this round table is ethical issues in the Indian
health care sector and we have speakers from different
parts of the value chain to get practitioner inputs on ethical
behaviour in health care. I will start by alluding to Nobel
Prize winning economist Kenneth Arrow’s seminal paper
from1963,4 where he first talks about the curious nature of
‘uncertainty’ in health care markets that engenders
particular problems of adverse selection and moral hazard.
Arrow also focused on the physician-centricity of health
care markets, where the final consumer and the provider
are almost always intermediated by an agent in-between,
the physician concerned in most cases. Since the area is
vast what we will try today is to cover various issues with
Professor Arrow’s thoughts in the background. It is also
a pleasure to bring in Richard, Ravi, Deepak, and Rijit in the
ambit of this discussion. They come from various parts of
the value chain in the industry and their thoughts poten-
tially will cover the entire gamut of issues relevant to
health care markets and ethical behaviour. Over to you
Richard.
Richard Manning
Ethics in health care
Given my background, it is natural for me to think about
things in terms of efficiency and markets. My view is that
a discussion of ethics needs to be grounded in a recognitionthat people will tend to act in ways that they perceive to be
in their own best interest. When society has in place
appropriate structures and protections, individuals acting
in their own interest often lead to outcomes that leave
others better off as well. Not to be trite, but my view is that
Adam Smith was keenfully insightful when he described
the power of the “invisible hand.” Economic growth and
development have done a great deal to lift individuals out
of poverty and to foster prosperity in societies. There is
a great deal of overlap between the search for economic
efficiency and the betterment of mankind, which is to me
a key standard by which ethical behaviour ought to be
measured. As economies, particularly the emerging econ-
omies, continue to grow, individuals will desire more and
better quality of life. Health care can be a major compo-
nent of that improved quality of life and can be an impor-
tant factor in enabling continued economic growth and
development.
In short, the ethical responsibilities held by both
governments and biopharmaceutical companies have to do
with allowing/helping individuals achieve their goals with
respect to quality of life. As economies grow, individuals
will naturally desire better quality of health care for
themselves and those they care about. The rules govern-
ments put in place can either foster or retard that progress.
Two key issues in ethics: pricing and marketing
Pricing
Relative to the pharmaceutical industry, no issue raises
more ethical considerations in the emerging markets (or in
the developed ones) than pricing.
Ethical issues in pricing cluster around two poles: 1)
providing access to existing medicines for those that cannot
pay and 2) maintaining the incentive to continue to develop
medicines that address unmet needs. Essentially these
problems come down to caring for the needs of present
patients as opposed to caring for the needs of future
patients. Critics of the pharmaceutical industry sometimes
appear to give too little attention to the latter; the industry
sometimes appears to give too little attention to the
former. In fact, a wholly ethical approach to the problem of
pricing must consider both current and future needs.
Some argue that the developed world is a sufficiently
large and wealthy market to bring forth innovation in
medicines and that ignoring the property rights of compa-
nies in lower income countries through compulsory
licensing, voiding of patents, strict price controls, or
whatever mechanism can do no meaningful harm to the
future flow of medicines. For medicines that treat condi-
tions prevalent in both developed and emerging markets, it
is almost certainly true that the lost sales from “free
riding” in low income countries are not a large deterrent to
innovation at least in the near term. However, such static
effects are not the only ethical consideration.
Companies that might start selling at very low prices in
lower income markets have a natural interest in moving into
higher incomemarkets, and products sold at lowprices in low
income countries will naturally tend to flow into higher
income markets whether through legitimate channels or
Ethical issues in health care sector in India 55otherwise. Additionally, generics manufacturers seeing
opportunities to challenge patents in developed countries
have an incentive to turn their attention to those markets as
well. Both these forces threaten to leave those with low
incomes without the supply they need.
Additionally, as the emerging markets countries to grow,
they become meaningful markets and larger and larger
segments of their populations will have the capacity to pay
for innovative medicines. Should they not? Is there no
ethical responsibility for people who can afford to pay for
innovative products to do so regardless of where they live?
A key example of this tension, and the need to solve it, is
HIV. Thanks to innovation in medicines, access to appro-
priate medications can turn this disease into a manageable
health challenge. Without access, it remains a nearly
certain death sentence. The gains to treatment are
exceptionally large as it allows people to remain productive
in the most productive years of their lives. Although more
remains to be done, great progress has been made to foster
access to HIV therapies and to bring down their cost to
those that cannot pay.
Philipson and Jena5 demonstrated that despite the rela-
tively high perceived prices for the medicines, the compa-
nies that developed HIV therapies captured only about 5% of
the value of their innovation. In short, prices could easily
have been much higher and patients would still have
captured the bulk of the gains from the new therapies.
To current beneficiaries this is obviously good. However,
trouble looms due to dynamic factors. The HIV virus
mutates over time and the medicines that currently keep it
at bay will probably not always do so. Short of eradicating
the virus, which is most likely impossible, there will be
a continuing need for new HIV therapies over time. Who will
develop those? As prices are driven down naturally by
patent expiration and perhaps less naturally through
political pressure, the potential reward to the innovator
that brings new HIV therapies to market become small.
Today there are relatively few HIV research programmes
under way. Without an incentive to continue the search for
cures, the gains of the present are coming at the expense of
the gains in the future.
The challenge in HIV and other therapeutic areas is to
make products available for people that are unable to pay
while not destroying the markets for those that are able.
That is no simple task as it pits the interest of the present
against the interests of the future.
One potential solution to the dynamic efficiency
problem is fostering differential pricing through partner-
ships among private companies, NGOs and governments. In
a functioning differential pricing system, individuals or
population segments that can afford to pay only nominal
prices (or perhaps no price at all) would have drug supplies
segregated to allow them access while not threatening
existing commercial markets. While simple in concept, the
application is extremely difficult. Efforts have been made
to develop differential pricing schemes, but the alignment
of interests is very challenging. Making real progress will
require the commitment of various parties to ignore strong
immediate interests. Exactly how to obtain that commit-
ment is unclear.
Finally, although private companies have demonstrated
a willingness to invest in treatments for neglected diseases,those efforts have not and cannot be central to their
mission. While economic growth and development will go
a long way towards lessening the burden of those diseases,
many scholars agree that some non-market mechanisms
will be necessary to address those issues. While these ideas
have resulted in some successes, meaningful progress has
not yet been achieved.
An interesting question in this realm is who has the
ethical responsibility to bear the burden for research into
treatments for neglected diseases? No doubt, because the
infrastructure of discovery and development that already
resides in the private biopharmaceutical companies
conveys on them a cost advantage in the search for new
cures, they will play a role. Exactly what the dimensions of
that role should be seems less obvious. Certainly those
companies have financial resources, but that alone should
not lead them to bear the burden alone.
On the one hand, recent market developments have
knocked the innovative industry down the ranks of most
profitable companies in the world. Both in the US and on
a global scale, companies with the largest market value and
income reside largely in the oil and finance industries or in
information technology. If ethical responsibility is appor-
tioned according to ability to pay, certainly a wider set of
contributors than the biopharmaceutical companies would
be identified. Additionally, why is it that shareholders of
private companies should support this cause? Are they the
disproportionate beneficiaries? The answer to the question
is not obvious. Who should pay for the benefit of others is
not something about which economics typically has a lot to
offer. It only seems clear that the answer is unclear.
Ethics and marketing
A second key issue involving ethics in health care is the
marketing of prescription drugs. As in any industry, there
are legitimate concerns about the incentives the seller of
a good might have to distort information conveyed about
their product. In health care, this concern is heightened by
the fact that the ultimate consumer, the patient, is typi-
cally somewhat disconnected from the choice of medical
approach to use. When the physician acts in the patient’s
best interest, the ethical concern about marketing is less
serious. So a first step in thinking about the ethical chal-
lenge in marketing pharmaceuticals might be to consider
the incentives facing the care-giving physician. When
patients have the ability and freedom to compare and
select a physician based on how well he or she represents
the patient’s interest, the concern that the physician might
be unduly swayed by marketing efforts of the pharmaceu-
tical company is diminished.
It is also important to recognise that marketing activities
are a means of providing information to people as they
make economic choices. Information is costly to acquire
and process. Brands and trademarks exist because they
convey information to consumers about characteristics of
a good or service at a relatively low cost. Advertisers
remind people of their goods and service offerings because
people have many things to pay attention to and reminders
can help sort through information to help people decide
what to do with scarce time and resources.
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therapeutic recommendations to patients when they know
more about the products they prescribe. Although in
a perfect world, it might seem desirable for physicians and
patients to learn all they need to know from completely
disinterested parties, the reality is that pharmaceutical
companies know more about their products than anyone
else, and absolutely independent sources of information
are costly to acquire. In modern health care systems,
a physician’s time is scarce. Although academic publica-
tions provide an important source of new information, the
cost of staying on top of the latest advances is not small.
Hence, allowing companies to provide information to
patients and physicians can be an important component of
improved quality of care. It is common among economists
to argue that the best solution to concerns about biases in
the provision of information is the provision of more
information. When competitors each convey information to
physicians, they are able to determine credibility of various
sources and filter out better from worse.
Of course, inappropriate inducements to prescribe
specific products should not be allowed, but it is easy to go
too far and forget that the provision of information is
a complicated, costly, and valuable exercise. Sometimes
combining lunch or dinner with information about medical
treatment may be a problem, but sometimes it may be the
best way to lower the cost of the physician obtaining that
information. Limiting contact between physicians and
marketing professionals can have unintended consequences.
A recently publishedarticle6 examined the impact of access
to sales representatives in the US on prescribing patterns of
physicians treating cardiovascular and diabetes patients.
Perhaps not surprisingly, the study found that physicians
working in settings with greater access to pharmaceutical
company representatives had more rapid adoption of new
medicines than those working in settings with restricted
access to sales representatives. One can argue about the
merits of rapid response to the launch of a new medicine.
Certainly, however, delaying treatment in cases where
a new medicine would provide a substantial benefit to
patients presents an ethical problem.
A more obvious ethical problem would be continuing to
expose patients to a newly discovered risk. Importantly,
Chressanthis and his colleagues found evidence that this
was an unintended consequence of restricting interactions
between physicians and sales professionals. Physicians in
their sample that had low access to sales reps took signifi-
cantly longer to reduce prescribing in response to a newly
discovered risk than those with high access to sales
professionals.
Of course, the applicability of these specific findings to
India or other emerging markets with different information
structures, different regulatory environments and different
education levels is not obvious, but the reality that infor-
mation is costly and that providing more information allows
people to make better decisions is universal. Allowing
manufacturers to provide information to professionals and
perhaps to patients as well is a fundamental step along the
ethical course. Any structure that dictates the conditions
on which information can flow should account for the
potential gains from having more and better information in
the hands of prescribers and patients.Rijit Sengupta
Regulation in the health sector and the realities of
implementation
Ethics and health care
I have segregated my presentation on regulation in the
health sector into six sub-points. The first point is
a comment on the topic itself. There are two leading words
in the topic: one is “ethics” and the other is “health care”.
As far as ethics is concerned, we now have the National
Voluntary Guidelines (NVG) on Social, Environmental,
Economic Responsibilities of Business, which was adopted
by the Government of India, Ministry of Corporate Affairs.
The NVG tries to define responsible business conduct and it
presents a framework consisting of nine principles with
certain core elements to actualise each of the principles.
We can use principle one of the NVG to lay out broadly what
we mean by ethics in business and apply that specifically in
the health care sector. Principle one, which states that
businesses should conduct and govern themselves with
ethics, transparency and accountability, emphasises that
ethical conduct in all its functions and processes is the
cornerstone of responsible business. There is an emphasis
on the accepted or written and non-written codes, and
principles and values which define ethical behaviour. It
emphasises transparent communication and a culture of
integrity. It asserts that businesses should refrain from
indulging in corrupt practices and honestly discharge their
responsibility on financial and other areas pertaining to
mandatory disclosures.
Health care market
What do we understand by the term “health care market”
and what are its salient features in the context of this
discussion? First, the health care market is an extremely
diverse market as far as the states are concerned, given that
health care is a state subject. Second, it is characterised by
considerable information asymmetry. Third, it is driven by
a weak market regulatory framework which does not have
a very satisfactory implementation record. As far as the topic
is concerned, when you talk about health care from a holistic
perspective, it is difficult to separate practices in the phar-
maceutical sub-sector from the health care sub-sector. The
pharmaceutical sector is extremely heterogeneous and has
been undergoing considerable consolidation through
mergers and acquisitions recently. This is going to change the
topography of the pharmaceutical sector as far as the nature
and kind of players are concerned. The health care sector is
equally heterogeneous, an extremely dispersed and unreg-
ulated market. It is often difficult to identify the scope/
borders of this market.
Regulation of the health care/pharma sector
My next point is about regulation in the health care sector
and I will enumerate certain issues related to the experi-
ence of regulatory enforcement in this sector. The first is
about pharmaceutical pricing. The National Pharmaceutical
Pricing Authority (NPPA) which is the regulator for prices in
the pharmaceutical market is located under the Depart-
ment of Pharmaceuticals which is situated under the
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health care here and the Ministry of Health and Family
Welfare should have been the ministry or the custodian of
the drug regulator in this case. The NPPA’s motto is to serve
the consumers while encouraging the pharmaceutical
manufacturers to produce adequate quantity of quality
products to meet the rising demand. However, we know
from experience that often protecting the interests of the
industry becomes a priority over protecting the interests of
the consumers. For instance, if you look at the list of
essential medicines, there has been a considerable reduc-
tion in the number of medicines which are covered in the
National List of Essential Medicines (NLEM) over time. While
at the same time more and more private companies have
been given licenses to produce drugs in our country.
The second point about regulatory enforcement is about
the quality of the drugswhich are available in themarket and
what the regulator has done in order to ensure that quality is
maintained. The Central Drug Standard Control Organisation
(CDSCO) which controls the in-flow of drugs into the country
and oversees clinical trials, is placed under the Ministry of
Health and Family welfare. However, if you discuss issues
with them, they say that their sole responsibility is to ensure
that they provide licenses to international firms entering the
market. The license for domestic drug firms is provided by
the state drug controllers, who are also responsible for
monitoring the performance of these firms in the market
with regard to availability and quality of the drugs they
produce. Having worked in this sector for the last few years,
CUTS feels that if the enforcement of such regulatory
responsibility (of availability and quality of drugs in the
market) is left with the state, it might be counter-
productive. There is a large variation in the capacity of the
state drug controller and also in factors that determine the
market at state-level. In one of our recent projects7 for
example, we met with the drug controller of one state who
used modern technology and was able to locate or monitor
the activities of the drug inspectors across various locations
of the state on his fingertips. This state drug controller was
fairly well endowedwith resources.Whenwe visited another
state and met with the drug controller there, we realised
that hehadweak resource base (both physical and in terms of
human resources), which had implications on the perfor-
mance of this drug controller (ability tomonitor and regulate
the sector). So, there is a need to re-visit the approach
(driven by the present policy framework/administrative
arrangement) where the state drug controller monitors the
performance of the drug firms in the state. One cannot
expect a weak (state level) regulator to effectively regulate
such an extremely strong sector at the state level.
The third issue concerns marketing. Under the Indian
Medical Council (Professional Conduct, Etiquette and Ethics)
Regulations, 2002, pharmaceutical companies are not
supposed to influence the behaviour of doctors by offering
gifts/commissions. But evidence suggests otherwise, going
by the large number of complaints which have been received
by the MCI about such practices. Recently there has been an
attempt by the Health Ministry to come up with a Uniform
Code of Pharmaceutical Marketing Practices (UCPMP). It is
a voluntary guideline but theministry is very keen to enforce
it given the prevailing concerns related tomarketing of drugs
in the country.The fourth and the last point pertaining to experiences
in regulation is registration of health care institutions. The
Clinical Establishment Act, 2010, which was notified earlier
in May 2012, still remains a model law and is yet to be
adopted and adapted across most of the states. Only seven
states have adopted this Act to date, namely, Arunachal
Pradesh, Himachal Pradesh, Uttar Pradesh, Rajasthan,
Jharkhand, Mizoram, and Sikkim, and the Union Territories.
There is still a lot of resistance from the states in adopting
the Clinical Establishment Act. Related to this, in terms of
the performance of the health care institutions, according
to the National Antibiotic Policy of 2010, the government
has been toying with the idea of prescription audit to assess
adherence to “rational use of drugs” (RuD) by the doctors
and health care institutions. But there has been resistance
to this suggestion, especially from the Drug Traders Asso-
ciations in the country.
Recently, there were reports in the media about
continuing friction between the Planning Commission
(Government of India) and the Ministry of Health and Family
Welfare regarding recommendations made by the High
Level Expert Group on Universal Health Care headed by Dr.
Srinivas Reddy. If one looks at the chapter on Health in the
Five Year Plan (2012e17), it talks more about managed care
which has not gone down well with the Ministry of Health
and Family Welfare for obvious reasons. The Health Ministry
had hoped to receive greater financial support for
enhancing the capacity of the sector to provide better
health services, especially to the poor.
It is appalling that our country still doesn’t have
a National Health Policy. A draft has been lingering for
a long time. There is a lack of political will in supporting
and streamlining the health care sector as far as regulations
are concerned, which has had major implications for
a majority of our fellow citizens. The first is the high cost of
health care, and according to a World Bank estimate based
on 2004 data, several million households fall into poverty in
our country due to high health care expenses in India.
Private health care
The next concern is about private health care expenditures
in our country and implications for the economically disad-
vantaged. According to a report,8 private expenses in health
care constitute 80% of the total health care expenses in
India, which is very high as compared to other developing
countries. The issue which is of even more concern is that
expenditure on drugs comprises 72% of the total out-of-
pocket expenses in our country. A third issue on which we
have done some work9 is the nexus between various health
care providers in the country. In our report prepared on
the basis of primary information gathered from the two
statese Assam and Chhattisgarhewhat we sawwas that the
pharmaceutical companies were continuing to influence
doctors through promises of foreign visits and continued
medical education. The job of the medical representatives
too has become part of this loop.
Another thing that we need to think about is the size of
the pharmaceutical industry in the country e do we need so
many pharmaceutical companies/drugs in the market? The
nexus between the doctor and the diagnostic clinic is
considered as “usual practice” and operationalised through
“cuts and commissions” even though this is prevented
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alone that is affected by these kinds of practices. Even in
public health care, we have evidence to suggest deliberate
suppression of medicine supply in public hospitals, of
consumers being forced to go outside public hospitals for
medicines which were otherwise available at low cost (or
no cost) from the medical store within the public hospitals.
We need to deliberate on the kind of regulations that we
are looking at and looking for.
Co-regulation and self-regulation
There has been a considerable amount of stress on public
regulation and we have ignored the two other extremely
important types of regulation: the first being co-regulation,
and the other, voluntary self-regulation. Co-regulation sees
the government regulating through the sectoral association
(i.e., the pharmaceutical association in the pharmaceutical
sector and hospital association in the health care sector).
We have seen that sectoral associations have remained
extremely meek in monitoring the behaviour of their
members. We need to find ways in which the government
can work hand in hand with sectoral associations and
empower them. The sectoral associations must become
more active and penalise members who are indulging in
malpractices and/or not complying with applicable rules
that have implications on their behaviour.
The most appropriate analogy that I was able to draw
was of a school where you have a teacher who disciplines
the class; she can be equated with the public regulator/
government. Yet you also have a monitor who is elected
from within the class but is accountable to the teacher. This
is the role that sectoral association should carry out, and
remain accountable to the government. This is probably the
kind of model we need to explore for the pharmaceutical
and health care sectors. It is time to see how that can be
done. It is also necessary to assess the catalytic forces for
self-regulation, and promote them in the sector.
Role of CUTS
Finally, I would like to inform you about our organisation
and what we are doing to deal with this situation as
a consumer protection organisation. Firstly, we are trying
to gather some of the evidence that is otherwise difficult to
get and use that to raise a debate on the need for reviewing
the regulatory framework for the sector. Secondly, we are
trying to push the agenda that the main objective of the
pharmaceutical or the health care sector is to promote
consumer interest. Unlike in any other purely economic
sector such as steel, retail, apparel or automobile e
consumer/public interest issues are of prime interest in the
pharmaceutical and health care sectors. Therefore, the
geography and the framework for regulation are different
and have to be resolved by the government, both at the
central and the state level.
We have to see how we can promote the NVG to effect
a more responsible pharmaceutical, medical or health care
sector in India e such discussions/processes should not be
restricted to the national level but should take place across
the states.
There has to be a consistent process or forum to ensure
transparency across implementation of public regulation atthe level of the state. Even with co-regulatory activities,
for e.g. the sectoral regulation, much depends on the
nature of the market and that requires some thought. We
have also been lobbying for the adoption of the national
competition policy in India, looking into the policy imped-
iments that have hindered a level playing field in the
pharmaceutical sector, and affected entry and operations
of pharma firms in the country. We try to balance both: as
a consumer organisation we try to enforce the agenda of
consumer protection on the one hand, while on the other
we try to assess what is good for the industry.
Deepak Sapra
Ethics in health care
My starting point for any discussion on health care ethics is
the fact that it is imperative for a society to have healthy
citizens and therefore provision of universal, affordable
health care should be a core objective.
The other fundamental premise is that health care is an
important aspect of our life and part of the society we live
in. So any discussion on ethics in health care cannot be in
isolation of ethics in society.
I want to list out some of themajor issues that I see around
health care and especially pharmaceuticals where the
question of ethics comes in and there are several grey areas.
We use terms like health “care”, and pharmaceutical
“industry”, and pharmaceutical “market”. While these are
seemingly just definitions, the words used in these terms
appear to be at odds with each othere “care” and “industry”,
“care” and “market”. The question is whether we can recon-
cile these intended outcomes in a manner that is winewin.
Some of the issues I wish to point out are
 Drug pricinge Are drugs priced in amanner that they can
serve the needs of people who need them? Can pricing
improve access? To what extent do market forces help in
shaping pricing and impacting accessibility.
How does pricing link to who the payer is, i.e. whether it
is out of pocket, insurance company, or the state?
 Drug discovery e are the efforts towards research tar-
getted to those segments where there are glaring
health care gaps?
 Influencing doctors and other health care service
providers in order to generate prescriptions.What kind of
influence is acceptable e scientific, medical, academic,
commercial.
Where do the lines get blurred?
 Pharmaceutical research and clinical trials (CTs) e How
much of it is ethical and to what extent do we go?
Drug pricing
I would like to share some specific examples. Let me start
with the example of AIDS which is prevalent in several parts
of the world, including some of its most disadvantaged
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and Southeast Asia. Typically the cost of first line therapy
for an individual afflicted with AIDS used to be $50e60$ per
day irrespective of which part of the world the individual
lived in. As a consequence, many people were denied
access because the drugs were simply unaffordable, espe-
cially so as several patients were living at below $1 a day
With genericisation and competition, several players came
in, providing cheaper versions of the same therapy which
led to costs coming down to $1 a day. My next example is of
Rituximab, a monoclonal antibody, the biosimilar version of
which is manufactured by Dr Reddy’s, the company I work
for. The number of patients in India who were deriving the
benefit of this therapy was a handful, a few thousand, when
the product was being sold only by Company X, the inno-
vator. Enter the biosimilar version, at a price point that was
about 50% lower, and the number of patients getting
benefitted expanded dramatically to several fold. Thus, for
the right kind of price and the right kind of free market
play, there can be a substantial impact on the number of
beneficiaries. This can be especially effective in scenarios
where the payer pays from the pocket, in countries such as
India, Brazil, Latin America, Africa, and other parts of
Southeast Asia. The coming in of competition immensely
increases affordability. While these kinds of drugs are still
very expensive for several patients, the coverage increases
disproportionately with the fall in price.
This is one of the most important issues around ethics
and health care. It should be possible for someone to access
an intervention/drug at the right time and in a manner that
doesn’t cripple him/her financially. This is a very important
issue that generic companies and competition in the phar-
maceutical space have been able to address. I feel happy
and proud to be a part of this sector in India especially
because we are making a tremendous impact towards
improving the affordability of drugs, in every part of the
world.Drug discovery
Drug development is a high risk, high investment and
resource intensive game. It takes 10e12 years to get a drug
to the market; it costs anywhere between USD 800 mn to
a billion. If companies cannot recoup the money, as
corporations they will find it difficult to invest in specific
areas. This determines choice of areas to invest in, and
commercial attractiveness often scores over public health
concerns. This is one reason we see so many new drugs in
the neuropsychiatry space and so little, for example, in
tuberculosis.
As a synthesis, we must harness and leverage the power
of free markets with the benefits of collaboration, espe-
cially on research in areas of public health concerns.
Technology is an enabler and the more we use it to impact
how drugs are researched and manufactured, and how
diseases are diagnosed, the easier it will be for new drugs
to get to the market.
Investments in research also have to be a collaborative
effort between the public and private sectors with higher
funding for non-profitable drugs. Several old diseases, for
example malaria, are coming back with a vengeance andthere are no drugs targetting such resurgence. We must
provide incentives and funding for the right kind of research.
Influencing doctors
The third issue is around influencing doctors and others in
the industry on the drugs that are prescribed. Many phar-
maceutical companies have been questioned or criticised
for the way they achieve their financial targets, and the
financial metrics that they adopt, for example, categorising
doctors by the value of prescriptions they generate, and
the methods used to influence doctors and generate
prescriptions. Even with regard to unbranded generics,
concerns have been raised in the US about influence over
another set of players in the value chain e the pharmacy
chains, aggregators, and super markets, who are customers
and influence drug usage.
Clinical trials
Clinical trials are performed while establishing the safety
and efficacy of drugs intended for use on human beings.
There are a series of tests which need to be undertaken, on
healthy volunteers as well as patients. One of the most
controversial ones is the issue of trials on human beings. Are
we treating patients in the right manner? Are they aware of
what is happening? Are we providing the right kind of post-
trial support to volunteers? This impacts us in India a lot, as
India is a preferred CT destination owing to lower costs. One
estimate put the comparative cost of CTs in the ratio 1:4;
that is if it costs $10M in India, then it will cost $40M in theUS.
The important thing to note here is that there is a need for
transparency and this is not a very strongly established
system in India. Concerns have been cited about themedical,
ethical and financial treatment of volunteers and subjects. A
pharma report suggests that in 2012, more than 200 people
have died as a result of clinical trials in India. This brings us to
the question whether all was fair and square, and whether
the subjects weremade fully congnisant of the issues around
enrolment and subsequentmedical attention. So, how dowe
create health care ethically and legally?
There is debate around reducing clinical trials on humans,
wherever possible. Can we use more of technology and IT?
Can we use more statistical tools and be accepting of them?
Can we do more predictive in vitro experiments to reduce
in vivo activity? Can we formalise authorities’ responses, so
that there is mutual recognition of each other’s approvals?
Some of these questions could show us the way.Ravikumar Banda
Perspective on Indian health care
My perspective is likely to be different from that of the
other panellists on this subject. Let me tell you where I
come from. I have done my medicine, post-graduation in
psychiatry and I practised for some time. I then worked
with Astra Zeneca research foundation after which I started
my own company. So I have seen the industry from within,
plus I know what a medical practitioner feels.
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Health care is a very peculiar industry in that the consumer
has no rights. The consumer is completely governed by
a middleman who doesn’t pay for it, and that is the doctor.
In this situation, there is one thing that is quite frightening;
a clinician crossing ethical borders can cause lot more
damage than the pharmaceutical industry crossing the legal
borders. So we require phenomenal ethical regulation
which includes both the doctors and the other people
concerned within the same framework. To enable this, we
have one organisation, the MCI. While MCI is an august body
in this country, it has zero capability of enforcing regula-
tions or taking anybody to task. They do not have recourse
to legal aid that can help them to take action if something
goes wrong. Even when legalities have been breached by
clinicians it is very difficult for MCI to intervene and do
something about it when somebody complains to them.
They have to seek justice through the courts.
We have a paradoxical situation in this country, where
we have a huge disease burden when compared to the
Western world, but we are doing little to effectively
manage the abundant sickness. We have a lot of plans but I
don’t think we are implementing any of them.
The need for innovative health care delivery
What we require is two things, namely, inventions to tackle
some of these problems, and innovation in delivering the
solution to the last man in the remotest village. We lack
innovative health care delivery. Quite often, we blame the
person who invented the solution for the disease. We, the
government and society have been opportunistic. While
many people have been benefited by making some drug
generic we have killed innovation in the process. We don’t
see how we can keep the person still interested in the solu-
tion, in going further. At the end of the day, the pipeline will
dry up. Patent and patent protection is not a problem. The
problem lies in intellectual property rights (IPR) manage-
ment, the pricing of the new drug, negotiating with
a company when a new innovation has been made in making
that available to people, and so on. There we don’t have
solutions and we require a lot of inventions in that space.
However, we have the problem of poor performance
with regard to inventions, ethically as well as on the
management side. Big corporations are scared of investing
in inventions and SMEs are enthusiastic in niche areas, they
think that it can give them a unique position if they have
a new invention but they don’t have the money to see the
problem through. There are government initiatives such as
New Millennium Indian Technological Leadership initiative
(NMITLI), Biotechnology Industry Research Assistance Pro-
gramme (BIRAP), where part of the funding comes from
private initiatives. However, we have ethical issues when it
comes to supporting inventions in this country or supporting
funding. We have committees which look at publiceprivate
partnerships and they are worried that at the end of the
day, there is public money coming into a project that ulti-
mately can be taken up as a product in the private sector.
Though one may have price controls, it is the company that
makes a profit. They feel that the private investors in the
company have been made rich by expenditure at the
public’s expense. Amidst these confusions and ethical
dilemmas we forget that they there could be a public goodat the end of the process, and we lack the confidence that
a private company could make medicines affordable to
people. Since the product has come with peer-funding, it
comes with fewer problems, so the company could make it
more affordable.
They do not also understand the issues connected with
commercialisation of a product. Let me give you the
example of a company X that came up with a medical
diagnostic device that could be plugged into the Internet
and would provide excellent tele-medicine services, con-
necting doctors and patients in remote villages. But that
product has gone nowhere because of the insistence that
the price should be kept very low and within that pricing,
there was no distribution margin for 2e3 levels as required.
We need to think through the whole distribution chain and
incentivise the whole system, if not it won’t reach the last
man.
Ethical practices and positions
I now come to a problem that Rijit alluded to: the cuts
taken by doctors. It’s a huge problem in our diagnostics
industry. Where did the cuts get created? The doctors
blame it on pharmaceutical industry; I completely blame
the doctors. We need to have highest ethical practices with
diagnostics and drugs as the cuts and incentives add to the
patient’s burden. The doctors within their own fraternity,
and with the MCI and all the others concerned, need to get
together and see that the highest ethical standards are
maintained.
Let me demonstrate what I mean by unethical practice.
As a diagnostic provider let us say that I sell an HIV test kit
at a price between Rs. 17 and Rs. 25 depending on the tax
structure of that state to the hospital but the hospital in
turn charges the patient anywhere from Rs. 325 onwards. Is
there so much of value addition in the hospital on this
diagnostic kit? Definitely not. The charges are arbitrary and
this is largely an unethical practice. Hospitals are built at
a certain cost and they generally want to earn their costs
back on everything that goes through that hospital and
that’s where everything gets overcharged. I don’t know
who will control it, but it’s a huge problem in making health
care affordable in this country. Whatever the manufacturer
does, it does not reach the people because the hospital will
hike up the price.
Coming to the regulatory hurdles, we have a Central
Drugs Controller General of India (DCGI) who reports to the
Union Health Minister. Each state has a drug controller who
runs the day to day business of regulating, inspecting and
prosecuting. This is under each state government sepa-
rately and it is a very confusing situation for the industry
and it needs to be rectified. The second problem in this
area is the lack of a clearly defined work ethic. Even if we
put aside things like corruption, delay in issuing license e
sometimes for years together, is an unethical practice
which is not punished. On the other hand, if a drug is
granted a license and is used effectively for four years, and
in the fifth year there is a problem, the manufacturer will
be punished severely and the Drug Controller gets a black
mark. So many people feel that inaction is the best way.
This is how it is all over the world, not only in India.
However, the US FDI says there are ethics within that. If
a new drug is going to improve health care by even 5% or 2%
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ethical duty to see that the drug reaches society in the
shortest time. This is lacking in India. We have not ever
stated the ethical position, that it is also the duty of the
government to see that a drug reaches the people within
a stipulated time. Therefore, some ethics has to be brought
into the regulatory process. One important point that
everybody forgets, including the health ministry, is that if
we delay a drug then the cost of this delay is loaded on to
the price of the drug. We have to think through every delay
and include it in the process.
Public-private partnership
Next, I would like to continue what Deepak brought up e
about public-private partnership and the point of trust and I
will say that trust is lacking on both sides. Both the industry
and the bureaucracy are culpable in their own way but if we
keep blaming each other and carry on a game of one-
upmanship, this will go nowhere. At some point we need to
say stop and restore the ethical balance. The most impor-
tant aspect of this is, what is the effect on the ethics of the
whole society. We need to be responsible as a society on
many of these issues.
Let me give you an example from clinical trials. There
have been instances where committees working under the
Drugs Controller General of India (DCGI) have given oppo-
site decisions in similar situations. Very often committee
members though academically qualified do not understand
the ground realities of public health, and they take deci-
sions based on convenience.
It is a clinical trial which costs the maximum while
developing a drug. If we want to develop generic drugs,
which are important for the common man, we would
probably have the following situation. An anti-tuberculosis
drug was developed by a company in India, which went
through toxicology successfully, and through phase one of
the clinical trials, after which nothing further was heard
about the drug. Do you know why? The next step is a big
trial that would cost about S750M. The company is in
a dilemma whether to proceed or not because when this
product is successful, every country poor or rich will want
to procure it. It would be the governments of countries who
would want to procure it and they would negotiate over the
price. But who will finally pay for this $750M worth of
clinical trials? This dilemma could prevent the drug from
seeing the light of day because if this question is not
settled, the company could cap the drug indefinitely. This is
where public-private partnership can come into play.
Maybe the Government of India should permit the company
to conduct the clinical trial in India and negotiate for
a differential price in India. But nobody is doing that.
Everybody is willing to do what is called open source drug
discovery platform in which first discovery costs $100M or
less. That part they want to subsidise. But nobody is talking
about the remaining $650M. We need that kind of pub-
liceprivate partnership if you want to take the new drugs
which are invented elsewhere to the masses; you are
required to support them too and their inventions, other-
wise you will have a big problem of demoralising the
inventive companies.
The foremost point is we need to think about how to
bring ethics back into medical community back.Discussion
Vasanthi Srinivasan: Thank you. You have laid out the
range of issues on the subject of ethics in health care quite
comprehensively. The issues discussed reflect the
complexity of the sector, the multiple stakeholders
involved, the different interests of each of these stake-
holders, the weak regulatory framework, and the question
of self-regulation at the level of medical professionals and
organisations.
What would be the three recommendations or sugges-
tions that each of you has to any of the stakeholders that
would contribute to building a more ethical health care
systems?
Rijit Sengupta: A critical issue, which was raised by Ravi
as well, is the role of the drug controller (DCGI) both at the
centre and at the state level. The Ministry of Health and
Family Welfare must develop a mechanism that promotes
co-operation and consistency across the drug controller
functions in the states.
Most of the services in this country have a dedicated
sector regulator but the private health care sector (private
hospitals and clinics) neither has a regulatory framework
nor a regulator. The government must articulate its position
in terms of regulating the private health care sector, given
the proliferation of private providers in this sector which is
only going to increase. The third thing would be with regard
to the marketing of drugs. The government must move from
developing voluntary guidelines to stricter regulatory norms
as far as marketing and distribution of drugs is concerned.
These are my key recommendations.
Deepak Sapra: The core of my argument is based around
affordability and I have a few recommendations on that. In
the Indian context, one aspect that really impacts afford-
ability is the time it takes for drugs to get approval e this
aspect was pointed out by Ravi in his presentation. It would
be a very important aspect in health care overall. In order
to increase affordability we would have to reduce the time
it takes to get approval for various kinds of drugs and we
have to make sure of getting more people into the market
as early as possible. Another aspect, on the same point,
concerns the affordability of drugs which are still governed
by patent. On this my recommendation is that we must look
at compulsory licensing not just from the perspective of
patent protection but also from the perspective of number
of patients it is likely to impact. To my mind, compulsory
licensing could be one way, especially in certain critical
diseases where alternatives are not available. This could
get more drugs into the market in a manner that is
affordable to a wider mass of people in a country like India.
I am conscious that it is a very dangerous argument,
because it could open the flood gates and therefore you
need to be very careful. It needs to be selectively done in
the case of those products where there are no substitutes
available and where there is a real case for public health or
where a large number of patients are not being able to gain
the benefits of that medication.
My third point draws upon the emerging thinking around
innovation, which Ravi and Rijit also spoke of. I agree that
the scope for innovation in this sector is phenomenally high
at the moment because of the various kinds of possibilities
62 C. Chatterjee, V. Srinivasanthat exist in the value chain. My recommendation to
venture capitalists would be to be consciously on the
lookout for the models which incorporate innovation in the
health care industry, especially around delivery, and to
start in places which are not conventionally considered
important markets or important customer segments. There
is a lot of value at the bottom of the pyramid and there is
a lot of value in taking it forward. There are various inno-
vative approaches that people are trying out and people
have done it in different parts of the world. We should be
able to encourage innovation and get it into the Indian
scenario. Another aspect I would like to draw attention to is
that there is tremendous potential to leverage technology
to reduce many of the barriers that exist, especially around
information asymmetry. We could collaborate with the
leaders in the field over this.
Vasanthi Srinivasan: I have a PhD student who is
researching on scaling up of health care services and one of
his areas of interest has been telemedicine. Many tele-
medicine initiatives have been announced in the public-
private partnership mode but the incentive structures
that are built in are unclear. What is likely to be the future
of telemedicine given that it could enable affordable
access to health care in rural areas?
Deepak Sapra: For this, we would have to look at
collaboration with different players in the value chain.
Ravikumar Banda: Telemedicine is a subject close to my
heart. There are all sorts of problems around it and I have
seen companies struggle. The point in telemedicine is
taking the product to the end customer. How do you reach
it and how do you make the whole path smooth? It’s like
this: People say if you have a small margin and large
volume, it’s a great business to do in health care. But
reaching a large volume of people requires hectic
marketing and that’s a hugely expensive proposition. In
order to aim at very big markets, you should be able to
reach a large volume of people and that gap has to be first
looked at. There we need to think how to reach a large
sector of people without going through the classical phar-
maceutical marketing method, which is a very expensive
proposition. Only if we bridge that gap, I think more and
more innovations will occur which will simplify telemedi-
cine. People forget that if a farmer can be saved a trip from
his village to his city for medical consultation, he is willing
to pay for the telemedicine service. So we must think of
how we can cost telemedicine cleverly to make it acces-
sible to the end user.
To reply to Vasanthi’s question, my three suggestions
would be: Firstly we need to integrate MIC with the
enforcement agency. We need to have MCI tie up with IMAs
(which are very powerful bodies in this country) to inte-
grate all the doctors and put back a programme in which
they are exposed to ethical values and made aware of what
that would do to their practice. I think their own living will
improve. Secondly, we seem to have forgotten the existing
public health care system through general hospitals andmedical college hospitals attached. We were providing
good medicine through that system where the poor would
get a certain amount of care. Today they are all in
a dilapidated state, and we need to improve them. The
funds allotted by the World Bank to improve the public
health system are not being used effectively.
We need to urgently strengthen the public health care
system. Thirdly and most importantly we need to integrate
the regulatory mechanism of the pharmaceutical industry
into one body. We need to put in place much more rigour
and time lines in executing these regulations, be trans-
parent and evolve guidelines by involving the pharma
industry.
Vasanthi Srinivasan: Thank you all for making this such
an enlightening discussion.
Appendix A
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.iimb.2012.11.004.
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